TrialLancet (London, England)2017

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Anthony B El-Khoueiry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.